PGS Publication: PGP000451

Publication Information (EuropePMC)
Title Atopic polygenic risk score is associated with paradoxical eczema developing in psoriasis patients treated with biologics.
PubMed ID 36804406(Europe PMC)
doi 10.1016/j.jid.2023.01.021
Publication Date Feb. 15, 2023
Journal J Invest Dermatol
Author(s) Al-Janabi A, Eyre S, Foulkes AC, Khan AR, Dand N, Burova E, DeSilva B, Makrygeorgou A, Davies E, Smith CH, Griffiths CE, Morris AP, Warren RB, BSTOP Study Group and the BADBIR Study Group.
Released in PGS Catalog: April 12, 2023

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported

PGS Developed By This Publication

Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution
GWAS
Dev
Eval
 Scoring File (FTP Link)
PGS003486
(PRS_AE)
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 Atopic eczema atopic eczema 71
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003486/ScoringFiles/PGS003486.txt.gz
PGS003488
(PRS_IL12)
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 General atopic disease (IL-12 related variants) allergic disease 10
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003488/ScoringFiles/PGS003488.txt.gz
PGS003489
(PRS_IL17)
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 General atopic disease (IL-17 related variants) allergic disease 18
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003489/ScoringFiles/PGS003489.txt.gz
PGS003487
(PRS_IL4)
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 General atopic disease (IL-4 related variants) allergic disease 25
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003487/ScoringFiles/PGS003487.txt.gz
PGS003459
(PRS_CO)
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 Atopic eczema or atopic disease atopic eczema,
allergic disease		 170
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003459/ScoringFiles/PGS003459.txt.gz
PGS003458
(PRS_AT)
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 General atopic disease allergic disease 124
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003458/ScoringFiles/PGS003458.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		Evaluated Score PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM017413 PGS003458
(PRS_AT)
 PSS010186|
European Ancestry|
3,212 individuals
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 Reported Trait: Paradoxical eczema in biologic-treated psoriasis OR: 2.24 [1.2, 4.17] AUROC: 0.583 — PCs 1-2 —
PPM017415 PGS003487
(PRS_IL4)
 PSS010186|
European Ancestry|
3,212 individuals
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 Reported Trait: Paradoxical eczema in biologic-treated psoriasis OR: 2.08 [0.7, 6.06] — — PCs 1-2 —
PPM017416 PGS003488
(PRS_IL12)
 PSS010186|
European Ancestry|
3,212 individuals
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 Reported Trait: Paradoxical eczema in biologic-treated psoriasis OR: 4.89 [1.03, 23.29] — — PCs 1-2 —
PPM017417 PGS003489
(PRS_IL17)
 PSS010186|
European Ancestry|
3,212 individuals
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 Reported Trait: Paradoxical eczema in biologic-treated psoriasis OR: 1.55 [0.47, 5.14] — — PCs 1-2 —
PPM017412 PGS003486
(PRS_AE)
 PSS010186|
European Ancestry|
3,212 individuals
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 Reported Trait: Paradoxical eczema in biologic-treated psoriasis OR: 1.89 [1.08, 3.3] AUROC: 0.567 — PCs 1-2 —
PPM017414 PGS003459
(PRS_CO)
 PSS010186|
European Ancestry|
3,212 individuals
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 Reported Trait: Paradoxical eczema in biologic-treated psoriasis OR: 1.83 [1.17, 2.84] AUROC: 0.585 — PCs 1-2 —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS010186 Plaque psoriasis patients with at least one exposure to biologic therapy. Cases developed one or more paradoxical eczema adverse events during treatment with one of the following biologics: TNF-alpha inhibitors (adalimumab; etanercept; certolizumab; infliximab), IL-17 inhibitors (brodalumab; secukinumab; ixekizumab), IL-12/23 inhibitors (ustekinumab) and IL-23p19 inhibitors (guselkumab; risankizumab; tildrakizumab). Controls has no recorded eczema events during biologic therapy. Participants may have been exposed to more than one biologic. —
[
  • 88 cases
  • , 3,124 controls
]
 — European — BSTOP —